Lymphoma clinical trials in Arizona

34 actively recruiting lymphoma trials at 10 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT06091254). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $910,124 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $910,124

Paid for research work on this trial

DIPENKUMAR MODI $220,976
JOSHUA BRODY(oncologist on CancerDrs) $153,783
RUEMU BIRHIRAY(oncologist on CancerDrs) $81,618
NATALIE GROVER(oncologist on CancerDrs) $60,349
EMILY AYERS(oncologist on CancerDrs) $59,405

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT06588478). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $137,646 for research work on this study.

Who paid

Eli Lilly and Company $137,646

Paid for research work on this trial

JAMES D'OLIMPIO(oncologist on CancerDrs) $127,194
BITA FAKHRI(oncologist on CancerDrs) $1,307
BRUCE CHESON(oncologist on CancerDrs) $1,307
JACKSON GAO(oncologist on CancerDrs) $1,307
TARA GRAFF(oncologist on CancerDrs) $1,307

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04269902

Sites in Arizona:

Cancer Center at Saint Joseph's — Phoenix, Arizona
Banner University Medical Center - Tucson — Tucson, Arizona
University of Arizona Cancer Center-North Campus — Tucson, Arizona